Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
Type:
Grant
Filed:
June 5, 2015
Date of Patent:
August 14, 2018
Assignee:
Victoria Link Limited
Inventors:
Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
Abstract: The present invention relates to a hepato-protective beverage composition comprising a potable liquid, a primary hepato-protective agent comprising 18?-Glycyrrhizin or 18?-Glycyrrhizin or a combination thereof, and a complimentary hepato-protective agent comprising sugar or sugar alcohol or a combination thereof. The combination of effective amounts of the primary and complimentary hepato-protective agents provides hepato-protection and reduced toxicity caused by consumption of alcoholic beverages. The present invention also provides a beverage additive comprising these hepato-protective agents designed to be mixed with a potable liquid, providing the same beneficial results.
Abstract: The invention relates to processes for preparing (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside and compositions comprising the same.
Type:
Grant
Filed:
June 10, 2014
Date of Patent:
July 24, 2018
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Melpo Christofidou-Solomidou, Kyriacos C. Nicolaou, Roman A. Valiulin, Nicholas Simmons, Philipp M. Heretsch
Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:
Type:
Grant
Filed:
February 3, 2014
Date of Patent:
July 17, 2018
Assignee:
TAISHO PHARMACEUTICAL CO., LTD.
Inventors:
Daisuke Yamamoto, Fusayo Io, Koji Yamamoto
Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
Abstract: The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
Abstract: Disclosed is a new function of a small molecule metabolite glutamine. The small molecule can improve sensitivity of bacteria including antibiotic-resistant bacteria to antibiotics. Also disclosed is an application of glutamine in combination with glucose in improving sensitivity of bacteria to antibiotics.
Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
Type:
Grant
Filed:
December 6, 2016
Date of Patent:
March 27, 2018
Assignee:
Tricol Biomedical, Inc.
Inventors:
Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
Type:
Grant
Filed:
February 6, 2017
Date of Patent:
March 20, 2018
Assignee:
University Court of the University of Dundee
Abstract: Provided herein are methods for inducing cell death in a gram positive bacterium and methods for reducing the proliferation of a gram positive bacterium that include contacting a gram positive bacterium with a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are methods of treating a subject having a gram positive bacterial infection that include administering to a subject having a gram positive bacterial infection a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are compositions containing a dye (e.g., an azo dye) and a TarO inhibitor, and kits containing at least one of these compositions.
Abstract: A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.
Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
Type:
Grant
Filed:
November 28, 2013
Date of Patent:
January 30, 2018
Assignees:
Victoria Link Limited, University of Liverpool
Inventors:
Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
Type:
Grant
Filed:
March 4, 2015
Date of Patent:
December 19, 2017
Assignee:
Tricol Biomedical, Inc.
Inventors:
Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
October 10, 2017
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
Abstract: A process for the production of a refined dianhydrosugar-containing product is disclosed. The process includes controlled continuous crystallization of the dianhydrosugar-containing product to produce a solution saturated with the dianhydrosugar. The saturated solution is mechanically separated, for example by centrifugation, and the crystalline product is washed. The only solvent used is water. The dianhydrosugar-containing product is upgraded to at least 99.8% purity and recovery is 95% or greater. Recrystallization of the dianhydrosugar of 99.8% purity results in an ultra pure product containing at least 99.99% dianhydrosugar.
Type:
Grant
Filed:
April 9, 2009
Date of Patent:
September 19, 2017
Assignee:
Iowa Corn Promotion Board
Inventors:
Charles Guthrie Moyers, James Kermit Withrow, John Leonard Stephens
Abstract: The present invention provides a or therapeutic agent for HAM, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a HAM-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.
Type:
Grant
Filed:
May 27, 2014
Date of Patent:
September 5, 2017
Assignees:
PureCircle Sdn Bhd, The Coca-Cola Company
Abstract: Forming multifunctional materials and composites thereof includes contacting a first material having a plurality of oxygen-containing functional groups with a chalcogenide compound, and initiating a chemical reaction between the first material and the chalcogenide compound, thereby replacing oxygen in some of the oxygen-containing functional groups with chalcogen from the chalcogen-containing compound to yield a second material having chalcogen-containing functional groups and oxygen-containing functional groups. The first material is a carbonaceous material or a macromolecular material. A product including the second material is collected and may be processed further to yield a modified product or a composite.
Type:
Grant
Filed:
February 15, 2013
Date of Patent:
August 22, 2017
Assignee:
ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY